We have brought key accomplishments in understanding hallucinations, using language as a marker for psychosis, applying nutritional interventions to psychiatry and neurology, tapering antipsychotic medication and optimizing the treatment for women with psychosis.
The group has a proven track record in securing multimillion-euro grants, leading national and international consortia, communication with lay audience and publishing in high-impact journals. Our work is strongly interdisciplinary across multiple foci. We strong coalitions with partners in the field of linguistics, molecular imaging, microbiology, pharmacology, AI and gynecology, which enables us apply top-notch techniques and know-how to the field of neuropsychiatry.
Group mean of [11C]UCB-J Non-displaceable Binding Potential (BPND) PET-images in Schizophrenia Spectrum Disorder (SSD), their healthy siblings (SIB), and healthy controls (HC). The figure displays the average BPND PET-images of SSD (N - 24) (lower panel), SIB (N - 25) (middle panel), and HC (N = 26) (upper panel).
We strive to understand the mechanisms behind brain disorders like psychosis, and use this knowledge to accurately predict mental health crisis, which opens a window of opportunity to prevent such crisis. We also design and test innovative treatments which are better tailored to individual needs. Our main strengths are:
Bote Smid
E-mail: [email protected]
Center for Clinical Neuroscience and Cognition
University Medical Center Groningen
Triade building, entrance 24, room KZ1.06
Groningen
The Netherlands
